OpenAI's acquisition of Orchestra Bio

OpenAI acquired Orchestra Bio, a startup that builds AI agents to coordinate pharmaceutical drug development workflows. Orchestra Bio's agents track studies and timelines across drug programs, map which trials slip when a disruption such as a failed manufacturing batch occurs, and flag how a delay in one part of a program cascades through the rest. Orchestra Bio's team and technology will be integrated into Rosalind, OpenAI's suite of AI models and tools for life sciences researchers, which already includes GPT-Rosalind for biological and chemical reasoning and Rosalind Workbench for connecting models to lab instruments and data. OpenAI described the acquisition as targeting the coordination work that spreads a drug program across departments, contractors, and disconnected software, rather than the underlying science. Financial terms were not disclosed.